COMMUNIQUÉS West-GlobeNewswire

-
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07/03/2024 -
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
07/03/2024 -
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
07/03/2024 -
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
07/03/2024 -
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
07/03/2024 -
Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH
07/03/2024 -
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
07/03/2024 -
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
07/03/2024 -
MAPS Announces Celestial Plans for Its 38th Anniversary
07/03/2024 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 29, 2024
07/03/2024 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 29 février 2024
07/03/2024 -
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
07/03/2024 -
EssilorLuxottica and Dolce&Gabbana announce 16-year licensing renewal
07/03/2024 -
EssilorLuxottica et Dolce&Gabbana annoncent le renouvellement de leur accord de licence pour 16 ans
07/03/2024 -
DLH to Provide Information Technology Services to the National Cancer Institute
07/03/2024 -
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
07/03/2024 -
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/03/2024 -
Healthcare Financial Management Association calls Patient Rights Advocate’s latest price transparency compliance report ‘irresponsible’
07/03/2024 -
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
07/03/2024
Pages